Ken Griffin Genmab A/S Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$23.84 - $28.48 $81,056 - $96,832	3,400 Added 50.0%	10,200 $248,000
Q2 2024 Aug 14, 2024	SELL	$25.13 - $30.27 $165,858 - $199,782	-6,600 Reduced 49.25%	6,800 $170,000
Q1 2024 May 15, 2024	BUY	$26.43 - $32.77 $44,931 - $55,709	1,700 Added 14.53%	13,400 $400,000
Q4 2023 Feb 14, 2024	BUY	$27.94 - $35.44 $30,734 - $38,984	1,100 Added 10.38%	11,700 $372,000
Q3 2023 Nov 14, 2023	BUY	$35.27 - $42.24 $211,620 - $253,440	6,000 Added 130.43%	10,600 $373,000
Q2 2023 Aug 14, 2023	SELL	$37.4 - $42.94 $1.11 Million - $1.28 Million	-29,700 Reduced 86.59%	4,600 $174,000
Q1 2023 May 15, 2023	BUY	$34.88 - $43.22 $1.09 Million - $1.35 Million	31,300 Added 1043.33%	34,300 $1.3 Million
Q4 2022 Feb 14, 2023	SELL	$33.8 - $47.06 $5.75 Million - $8 Million	-170,100 Reduced 98.27%	3,000 $127,000
Q3 2022 Nov 14, 2022	BUY	$31.52 - $373.61 $2.89 Million - $34.2 Million	91,600 Added 112.39%	173,100 $5.56 Million

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.